Payment overview · 2025
General Payments
$956.05
49 reported records · 15 companies
Healthcare provider profile · identity verified
Eric B Johnson, PA-C
Physician Assistants & Advanced Practice Nursing Providers|Physician Assistant · OGDEN, UT · NPI 1841289600
Verified facts
What the public records show
CMS Open Payments records show Eric B Johnson, PA-C received $956.05 in general payments during 2025 across 49 reported records.
Amgen Inc. accounted for 28.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 24 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Abrysvo.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Synthroid by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ABRYSVO as an associated drug or biological on 55380 records involving 31565 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Abrysvo by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 38 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Paxlovid by this doctor in 2024.
SANOFI-AVENTIS U.S. LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SOLIQUA 100/33 as an associated drug or biological on 43 records involving 15 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Soliqua 100-33 by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Amgen Inc. | Unresolved — no canonical attribution shown | $268.32 | 28.1% | 8 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $173.47 | 18.1% | 15 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $164.67 | 17.2% | 7 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $75.05 | 7.8% | 4 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $62.34 | 6.5% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $48.11 | 5.0% | 3 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $34.63 | 3.6% | 2 | 2025 |
| ViiV Healthcare Company | Unresolved — no canonical attribution shown | $24.25 | 2.5% | 1 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $19.08 | 2.0% | 1 | 2025 |
| SANOFI-AVENTIS U.S. LLC | Unresolved — no canonical attribution shown | $17.79 | 1.9% | 1 | 2025 |
| Dynavax Technologies Corporation | Unresolved — no canonical attribution shown | $16.58 | 1.7% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $14.81 | 1.6% | 1 | 2025 |
| Verity Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $14.50 | 1.5% | 1 | 2025 |
| Gilead Sciences, Inc. | Unresolved — no canonical attribution shown | $14.39 | 1.5% | 1 | 2025 |
| Organon LLC | Unresolved — no canonical attribution shown | $8.06 | 0.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $956.05 | 49 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $246.20 | 5 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $113.56 | 12 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $82.74 | 4 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $64.41 | 3 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $62.34 | 2 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $59.91 | 3 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $54.78 | 3 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $48.11 | 3 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $48.11 | 3 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $32.50 | 2 | 2025 |
Source payment records
|
|||||
| APRETUDE Normalized: apretude |
Drug | ViiV Healthcare Company | $24.25 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $22.12 | 3 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $20.27 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $20.27 | 1 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $19.08 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $18.03 | 2 | 2025 |
Source payment records
|
|||||
| TZIELD Normalized: tzield |
Biological | SANOFI-AVENTIS U.S. LLC | $17.79 | 1 | 2025 |
Source payment records
|
|||||
| Heplisav-B Normalized: heplisav b |
Drug | Dynavax Technologies Corporation | $16.58 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $14.81 | 1 | 2025 |
Source payment records
|
|||||
| Tlando Normalized: tlando |
Drug | Verity Pharmaceuticals Inc. | $14.50 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $13.14 | 2 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $13.14 | 2 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $13.14 | 2 | 2025 |
Source payment records
|
|||||
| NEXPLANON Normalized: nexplanon |
Drug | Organon LLC | $8.06 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ABRYSVO abrysvo |
2025 | Abrysvo | 2024 | 14 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ABRYSVO open payments reported associated product |
CMS Open Payments — General Payments 55380 supporting records · 31565 recipient NPIs · example record 1228794147 |
Abrysvo · 2024 Exact normalized brand match · 1 Part D row |
14 | 13 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
38 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
14 | 13 |
| SANOFI-AVENTIS U.S. LLC Exact reporting entity; no affiliate inference |
2025 | SOLIQUA 100/33 open payments reported associated product |
CMS Open Payments — General Payments 43 supporting records · 15 recipient NPIs · example record 1233224976 |
Soliqua 100-33 · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Rosuvastatin Calcium | Rosuvastatin Calcium | 105 | 25 |
| Lisinopril | Lisinopril | 101 | 28 |
| Dexamethasone | Dexamethasone | 95 | 83 |
| Metformin Hcl Er | Metformin Hcl | 76 | 20 |
| Celecoxib | Celecoxib | 74 | 32 |
| Omeprazole | Omeprazole | 74 | 24 |
| Gabapentin | Gabapentin | 67 | 22 |
| Levothyroxine Sodium | Levothyroxine Sodium | 62 | 18 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 59 | 29 |
| Prednisone | Prednisone | 58 | 29 |
| Amlodipine Besylate | Amlodipine Besylate | 53 | 14 |
| Alprazolam | Alprazolam | 52 | suppressed |
| Lorazepam | Lorazepam | 49 | suppressed |
| Atorvastatin Calcium | Atorvastatin Calcium | 45 | 15 |
| Doxycycline Hyclate | Doxycycline Hyclate | 42 | 40 |
| Cephalexin | Cephalexin | 41 | 33 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 40 | 18 |
| Clonazepam | Clonazepam | 39 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 39 | 19 |
| Eliquis | Apixaban | 38 | suppressed |
| Famotidine | Famotidine | 37 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 37 | 15 |
| Losartan Potassium | Losartan Potassium | 36 | 13 |
| Allopurinol | Allopurinol | 35 | 13 |
| Meloxicam | Meloxicam | 33 | 13 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 31 | 30 |
| Tamsulosin Hcl | Tamsulosin Hcl | 29 | suppressed |
| Chlorthalidone | Chlorthalidone | 28 | suppressed |
| Metformin Hcl | Metformin Hcl | 28 | suppressed |
| Simvastatin | Simvastatin | 28 | suppressed |
| Valsartan | Valsartan | 28 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 27 | 26 |
| Ozempic | Semaglutide | 25 | suppressed |
| Rybelsus | Semaglutide | 25 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 23 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 20 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 19 | 16 |
| Duloxetine Hcl | Duloxetine Hcl | 19 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 19 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 19 | suppressed |
| Ibuprofen | Ibuprofen | 18 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 18 | suppressed |
| Carvedilol | Carvedilol | 17 | suppressed |
| Fluconazole | Fluconazole | 17 | 15 |
| Xarelto | Rivaroxaban | 17 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 16 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 16 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 16 | suppressed |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 16 | suppressed |
| Trulicity | Dulaglutide | 16 | suppressed |
| Abrysvo | Rsv Vacc, Pref A And Pref B/Pf | 14 | 13 |
| Jardiance | Empagliflozin | 14 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 14 | 13 |
| Potassium Chloride | Potassium Chloride | 14 | suppressed |
| Pregabalin | Pregabalin | 14 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 14 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 14 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 14 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 14 | 13 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 14 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 13 | suppressed |
| Januvia | Sitagliptin Phosphate | 13 | suppressed |
| Metoprolol Succinate | Metoprolol Succinate | 13 | suppressed |
| Roflumilast | Roflumilast | 13 | suppressed |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 13 | suppressed |
| Azithromycin | Azithromycin | 12 | 12 |
| Pantoprazole Sodium | Pantoprazole Sodium | 12 | suppressed |
| Synthroid | Levothyroxine Sodium | 12 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 12 | suppressed |
| Acyclovir | Acyclovir | 11 | suppressed |
| Colchicine | Colchicine | 11 | suppressed |
| Emgality Syringe | Galcanezumab-Gnlm | 11 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 11 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
| Methotrexate | Methotrexate Sodium | 11 | suppressed |
| Mirtazapine | Mirtazapine | 11 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 11 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $956.05 · 49 records | Amgen Inc. | ABRYSVO, APRETUDE, AREXVY, BREZTRI, CAPLYTA, COMIRNATY, EVENITY, Heplisav-B, MOUNJARO, NEXPLANON, NURTEC ODT, OTEZLA, PREVNAR 20, QULIPTA, REPATHA, SHINGRIX, TRELEGY ELLIPTA, TZIELD, Tlando, UBRELVY, VRAYLAR, Veozah, ZAVZPRET, ZEPBOUND | 9 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Abrysvo play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error